Neurowave Medical Technologies LLC and Alaven Pharmaceutical LLC Announce Licensing Agreement for Medical Device for the Treatment of Pregnancy Related Nausea and Vomiting (NVP)

Published: Dec 17, 2009

CHICAGO--(BUSINESS WIRE)--Neurowave Medical Technologies™ (“NMT”) and Alaven® Pharmaceutical (“Alaven”) have entered into an exclusive licensing agreement under which Alaven will commercialize NMT’s patented prescription neuromodulation pulse generator device for the treatment of pregnancy induced nausea and vomiting (“NVP”) in the United States.

Back to news